Reauthorization of Critical Path Public-Private Partnerships
This bill amends the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships. It increases the authorization of appropriations from $6,000,000 to $10,000,000 for each fiscal year from 2023 through 2027.
Key points
Increases authorized annual funding for the partnerships from $6 million to $10 million.
Sets the funding authorization period for fiscal years 2023 through 2027.
Expired
Citizen Poll